A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: design and rationale of the randomized Elderly-ACS 2 Study
Conclusion The Elderly-ACS 2 study is a multicenter, randomized trial comparing a strategy of dual antiplatelet therapy with a reduced dose of prasugrel with a standard dose of clopidogrel in elderly patients with ACS undergoing percutaneous revascularization. (The Elderly ACS 2 trial: NCT01777503)
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Angioplasty | Bleeding | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clopidogrel | Coronary Angioplasty | Diabetes | Endocrinology | Heart | Heart Attack | Ischemic Stroke | Percutaneous Coronary Intervention | Plavix | Stroke | Study